Correspondence 0001104659-25-003850 from BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893) (BTAI)
BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893)
Date: Jan. 15, 2025 · CIK: 0001720893 · Accession: 0001104659-25-003850
AI Filing Summary & Sentiment
File numbers found in text: 333-284224
Letter
BioXcel Therapeutics, Inc.
555 Long Wharf Drive
New Haven, CT 06511
January 15, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Washington, D.C. 20549
Attention: Alan Campbell
Re: BioXcel Therapeutics, Inc.
Registration Statement on Form S-3 Filed January 10, 2025
File No. 333-284224
Acceleration Request
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioXcel Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-284224) (as amended, the “Registration Statement”) be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to 4:30 p.m. Eastern Time on January 17, 2025 or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission. The Company hereby authorizes each of Emily J. Johns and Sarah Meinel of Honigman LLP, counsel to the Company, to make such request on its behalf.
Please confirm the effectiveness of the Registration Statement with Emily J. Johns of Honigman LLP by telephone at (616) 649-1908 or Sarah Meinel of Honigman LLP by telephone at (616) 649-1914 and that such effectiveness also be confirmed in writing.
[Signature page follows]
****
Sincerely,
BioXcel Therapeutics,
Inc.
Show Raw Text
CORRESP 1 filename1.htm BioXcel Therapeutics, Inc. 555 Long Wharf Drive New Haven, CT 06511 January 15, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Alan Campbell Re: BioXcel Therapeutics, Inc. Registration Statement on Form S-3 Filed January 10, 2025 File No. 333-284224 Acceleration Request Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioXcel Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-284224) (as amended, the “Registration Statement”) be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to 4:30 p.m. Eastern Time on January 17, 2025 or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission. The Company hereby authorizes each of Emily J. Johns and Sarah Meinel of Honigman LLP, counsel to the Company, to make such request on its behalf. Please confirm the effectiveness of the Registration Statement with Emily J. Johns of Honigman LLP by telephone at (616) 649-1908 or Sarah Meinel of Honigman LLP by telephone at (616) 649-1914 and that such effectiveness also be confirmed in writing. [Signature page follows] **** Sincerely, BioXcel Therapeutics, Inc. /s/ Richard Steinhart Richard Steinhart Chief Financial Officer cc: Emily J. Johns, Honigman LLP Sarah Meinel, Honigman LLP N. Danny Shulman, Honigman LLP Isaac Pasha, Honigman LLP